ARVO Annual Meeting

April 28 – May 2 Vancouver Convention Centre Vancouver, B.C.





Program Summary



Sunday, April 28		
Registration/Badge Printing	Main Lobby	7am-6pm
ARVO Central	Exhibit Hall	7am-6pm
Basic Clinical Lecture	East Ballroom B	8–10am
Symposia	See program listing	8–10am
Posters	See program listing	8–9:45am 1–2:45pm 3–4:45pm 5–6pm*
Exhibits	Exhibit Hall	8:30am=5pm
ARVO/Alcon Keynote Session	ARVO Ballroom	10:15–11:45am
Proctor Award Lecture	ARVO Ballroom	12noon_12:45pm
China-ARVO Networking Forum	West 301	1–2:30pm
SIGs/Workshops	See program listing	1–2:30pm
	West 223/224	•
Low Vision Cross-sectional Group		1–2:30pm
Papers Sunday Social to	See program listing	3–4:45pm
Sunday Social †	Vancouver Aquarium	7–10pm
Monday, April 29		
Registration/Badge Printing	Main Lobby	7am–6pm
ARVO Central	Exhibit Hall	7am–6pm
NAEVR Defense Briefing	West 109/110	7–8am
Posters	See program listing	8:15-10am 11:15am-1pm 4-5:45pm 6-7pm*
Papers/Minisymposia	See program listing	8:15-10am 11:15am -1pm 3:30-5:15pm
Exhibits	Exhibit Hall	8:30am–5pm
Section Business Meetings	See program listing	10:15–11am
Workshops	See program listing	1:15–2:45pm
SIGs	See program lisitng	1:15–2:45pm 7:30–9pm
Multi-Disciplinary Ophthalmic Imaging Cross-sectional Group	East Ballroom B	1:15–2:45pm
WEAVR Luncheon †	Harbour Ballroom	1:15–2:45pm
Friedenwald Award Lecture	ARVO Ballroom	3–3:45pm
Special Sessions	See program listing	7:30–9pm
Student/Trainee Social	West Ballroom Foyer	7:30–9pm
Tuesday, April 30	7100t Balliootti i Oyot	
Registration/Badge Printing	Main Lobby	7am-6pm
ARVO Central	Exhibit Hall	7an-6pm
Breakfast with the Experts†	Harbour Ballroom	7-8:30am
Exhibits	Exhibit Hall	
Posters		8:30am-5pm
	See program listing	8:45–10:30am 11:45–1:30pm 2:45–4:15pm 4:30–5:30pm*
Papers/Minisymposia	See program listing	8:45–10:30am 11:45–1:30pm 2:45–4:15pm
General Business Meeting	West 211	10:45–11:30am
Weisenfeld Award Lecture	ARVO Ballroom	1:45-2:30pm
MIT Outstanding Poster Award Competition	Exhibit Hall	4:15–6:30pm
ARVO/Champalimaud Award Lecture	ARVO Ballroom	5:45–6:45pm
Wednesday, May 1		
Registration/Badge Printing	Main Lobby	7am-6pm
ARVO Central	Exhibit Hall	7am-6pm
Posters	See program listing	8:15-10am 10:15-12noon 3-4:45pm 5-6pm*
Papers/Minisymposia	See program listing	8:15-10am 10:15-12noon 3-4:45pm
Exhibits	Exhibit Hall	8:30am-5pm
Genetics Cross-sectional Group	East Ballroom B	12:15–1:45pm
Workshops	See program listing	12:15–1:45pm
SIGs	See program listing	12:15–1:45pm 6:15–7:45pm
Cogan Award Lecture	ARVO Ballroom	2–2:45pm
Special Sessions	See program listing	6:15–7:45pm
Classical Concert	West 301	8–10pm
Karaoke Night †	Blackbird Public House	9pm–12midnight
Thursday, May 2	DIACKDII U F UDIIC TIUUSE	γριτ- ιΔιτίωτημε
	Main Labby	7am 4:20nm
Registration ADMO Control	Main Lobby	7am-4:30pm
ARVO Central	Exhibit Hall	7am–3pm
Symposia	See program listing	8–10am
Posters	See program listing	8–9:45am 10:15am–12noon 2–3pm*
Papers	See program listing	10:15am–12noon
SIGs/Workshops	See program listing	12:15–1:45pm
ARVO 2020 Kickoff Reception	Exhibit Hall	2–3pm
Beckman Argyros Award Lecture	ARVO Ballroom	3:15–4:15pm
ARVO/Alcon Keynote Session	ARVO Ballroom	4:30–6pm

 $^{^{\}star}$ All Poster Session (all first authors must be present at their poster)

[†] Separate registration required



Important Policies

Use of recording/photography/audiotape/video equipment: Recording by any means (photographing, audiotaping, videotaping) of any presentations or sessions at any ARVO Meeting is prohibited, except by an ARVO-authorized agent for official purposes or by First Authors who want to photograph their own poster presentations. Violators risk confiscation of their equipment and/or dismissal from the Annual Meeting as deemed appropriate by ARVO.

Commercial Relationships Policy: Presenters must state and display all applicable commercial relationships. For more information on this important policy, refer to the Commercial Relationships Index at arvo.org/program-summary.

Clinical Trials Registration Policy: All clinical trials that will be reported in ARVO Annual Meeting abstracts must be registered on a publicly available database. The required acknowledgement of the First Author, acting as the authorized agent for all authors, certifies that any research presented in the abstract that reports on a clinical trial is registered, and the registration location and number are included on the abstract, in compliance with the ARVO Statement on Registering Clinical Trials, arvo.org/About/policies/statement-on-registering-clinical-trials/. For more information on this policy, refer to the Clinical Trials Registration Index at arvo.org/program-summary.

Program Summary

Program Summary: Online at **arvo.org/program-summary.** Abstracts are referred to in the *Program Summary* by program number (not page number) and session number.

Online Planner: Abstracts may be viewed and printed from the online planner at arvo.org/annual-meeting/program/online-planner/.

ARVO 2019 Mobile App: Offers complete search functionality for the Annual Meeting Program. Plan your schedule or sync with your schedule in the Online Planner. Download from the App Store, Google Play and elsewhere.

Photography Release

By attending the ARVO Annual Meeting, attendees agree to allow their names, likenesses and images either in audio, photographic or video format recorded onsite to be used by ARVO and the ARVO Foundation for Eye Research for educational and promotional purposes.

Disclaimer

The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting online program materials and print publications aim to promote vision research and scientific discourse for educational purposes. ARVO accepts no responsibility for any products, presentations, opinions, statements or positions expressed; and inclusion of such material within the Meeting, the publications or posted online does not constitute an endorsement by ARVO.



Continuing Medical Education

ARVO is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ARVO designates this live activity for a maximum of 23.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please refer to the Pocket Guide for the complete CME information.

Table of Contents

How to Use the <i>Program Summary</i>	3
Meeting Rooms — Convention Center Maps	4
Association Information	
2018 - 2019 Board of Trustees	8
2018 - 2019 ARVO Foundation Board of Governors	
Staff	8
2019 Annual Meeting Information	
Annual Meeting Program Committee	g
In Remembrance	
ARVO Social Events	11
NAEVR Central	12
Future Annual Meetings	12
Daily Program Schedules	
(Scientific sessions in program number order)	
Sunday	13
Monday	
Tuesday	173
Wednesday	257
Thursday	
Indices	
Author Index	409

See arvo.org/program-summary for:

- ARVO Commercial Relationships Policy
- Commercial Relationships Index
- Statement on Registering Clinical Trials
- Clinical Trials Index
- Moderator Index

Children in the Convention Center

Children under 18 years old must be accompanied by a parent or guardian at all times. Parents/guardians who bring children into paper sessions must remove them immediately if they become disruptive. Children are not allowed to accompany parents/guardians in sessions/events where tickets are required or food is provided, except events for which children's tickets are available for purchase. Under no circumstances are children permitted in the exhibit hall during set-up or dismantle times.

© 2019 by the Association for Research in Vision and Ophthalmology, Inc. All rights reserved. Permission to republish any part of this book must be obtained in writing from the ARVO Chief Marketing and Communications Officer, prior to publication. Contact Marisa Lavine at mlavine@arvo.org.

855 — B0333 Trends in pathogens and antibiotic resistance of corneal culture isolates in infectious keratitis in Sao Paulo, Brazil, over a 5-year period. Luiza M. Oliveira, T. Tanaka, J. M. Kato, F. Rossi, J. N. Almeida Junior, T. R. Sabato di Gioia, V. B. Giglio, M. R. Alves, R. M. Santo. University of Sao Paulo

856 — B0334 The Resurgence of Ocular Syphilis in British Columbia: 2013-2016

A Retrospective Chart Review. Maryam

Eslami¹, G. Noureddin¹, S. Warner¹, T. Grennan^{3, 2}.

¹Ophthalmology and Visual Sciences, University of British Columbia; ²Infectious Disease, University of British Columbia; ³BC Centre for Disease Control

857 — B0335 Ocular syphilis: clinical manifestations and visual outcomes. Merav Koschitzky, K. Xu, S. Kiss. Ophthalmology, Weill Cornell Medicine

858 — *B0336* Candida keratitis: epidemiology, management, and clinical outcomes. *Grace L. Qiao¹, J. Ling¹, T. Wong², S. Yeung¹, A. Iovieno¹*. ¹Ophthalmology & Visual Sciences, University of British Columbia; ²Pathology, University of British Columbia

859 — *B0337* Singapore Ocular Tuberculosis Immunity Study (SPOTIS). *Ae Ra Kee¹, P. E. Hutchinson², J. E. Connolly³, N. Yawata⁴, J. Siak³, R. V. Agrawal¹. ¹Ophthalmology, Tan Tock Seng Hospital, National Healthcare Group; ²Microbiology and Immunology, National University of Singapore; ³Translational Immunology, Institute of Molecular and Cellular Biology; ⁴Ocular Inflammation & Immunology, Singapore Eye Research Institute; ⁵Singapore National Eye Centre*

860 — B0338 Collaborative Ocular Tuberculosis Study (COTS) Consensus guidelines on initiating antitubercular therapy in presumed tubercular choroiditis. Vishali Gupta¹, R. V. Agrawal^{2,3}, I. Testi⁴, S. Mahajan⁵, D. Raje⁶, A. Agarwal¹, D. Gunasekeran², J. H. Kempen⁷, Q. D. Nguyen⁵, C. Pavesio⁸. 'Post Graduate Institute of Medical Education and Research, Chandigarh, India.; ²Tan Tock Seng Hospital; ³Nanyang Technological University; ⁴Department of Ophthalmology, University of Padova; ⁵Byers Eye Institute, Stanford Medical School; ⁶MDS Bioanalytics; ⁷Massachusetts Eye and Ear Harvard Medical School; ⁸Moorfields Eye Hospital

861 — B0339 Collaborative Ocular Tuberculosis Study (COTS) consensus guidelines on initiating antitubercular therapy in presumed tubercular retinal vasculitis. Rupesh V. Agrawal^{1, 2}, I. Testi³, S. Mahajan⁴, D. Raje⁵, A. Agarwal⁶, D. Gunasekeran⁷, J. H. Kempen⁹, Q. D. Nguyen⁴, C. Pavesio⁸, V. Gupta⁶. ¹Ophthalmology, Tan Tock Seng Hospital; ²Nanyang Technological University; ³University of Padova; ⁴Byers Eye Institute, Stanford Medical School; ⁵MDS Bioanalytics; °Post Graduate Institute of Medical Education and Research; ⁷Tan Tock Seng Hospital; ⁸Moorfields Eye Hospital; ⁹Massachusetts Eye and Ear Harvard Medical School

862 — B0340 Collaborative Ocular Tuberculosis Study (COTS) Consensus guidelines on initiating antitubercular therapy in intermediate uveitis and panuveitis. Ilaria Testi¹, R. V. Agrawal^{2,3}, S. Mahajan⁴, D. Raje⁵, A. Agarwal⁶, D. Gunasekeran², J. H. Kempen⁷, Q. D. Nguyen⁴, C. Pavesio⁸, V. Gupta⁶. ¹Department of Ophthalmology, University of Padova; ²Tan Tock Seng Hospital; ³Nanyang Technological University; ⁴Byers Eye Institute, Stanford Medical School; ⁵MDS Bioanalytics; ⁶Post Graduate Institute of Medical Education and Research; ⁷Massachusetts Eye and Ear Harvard Medical School; ⁸Moorfields Eye Hospital

863 — *B0341* Microbial Keratitis After Penetrating and Endothelial Keratoplasty. Nicolas Dohse¹, T. D. Wibbelsman², S. Rapuano², K. Hammersmith², P. Nagra², C. J. Rapuano², Z. A. Syed². 'Sidney Kimmel Medical College; 'Wills Eye

864 — *B0342* Fumagillin in microsporidial keratitis. *Faisal Aljassar, S. Shoughy, K. Tabbara*. ophthalmology, The Eye Center

Hosptial

865 — B0343 Understanding fungal keratitis pathogenesis through a reverse-translational approach. Kevin K. Fuller^{1, 2}, M. E. Brown⁸, D. Giacalone⁷, J. Dunlap⁴, T. Lietman⁵, R. Cramer⁷, K. Dharmalingam⁶, M. Zegans^{3, 7}. ¹Ophthalmology, University of Oklahoma Health Sciences Center; ²Microbiology and Immunology, University of Oklahoma Health Sciences Center; 3Surgery, Dartmouth Hitchcock Medical Center; 4Molecular and Systems Biology, Geisel School of Medicine at Dartmouth; 5Ophthalmology, University of California at San Francisco; 6Proteomics, Aravind Medical Research Foundation; 7Microbiology and Immunology, Geisel School of Medicine at Dartmouth; 8Ophthalmology, Dean McGee Eye Institute

866 — B0344 Tissue eradication and clinical resolution of adult inclusion chlamydia conjunctivitis (AIC) after treatment with one cycle of oral Azithromycin. Ana-Catalina Rodriguez-Martinez, K. Mohamed-Noriega, M. L. Fernandez, C. Fernández de Luna, G. Villarreal-Mendez, F. Morales-Wong, J. Mohamed-Noriega, J. Mohamed-Hamsho. Ophthalmology department, Universidad Autónoma de Nuevo León, Hospital Universitario "Dr. José E. González", Facultad de Medicina, Dpto. Oftalmología

867 — B0345 Meta-analysis Reveals Multiple Disease Processes Underlying Trachoma.

Mohammad A. Tahboub¹, C. Castillejo²,
A. Sabbagh³, B. Lauinger¹, J. Aljabban², S.

McDermott², S. Frank², D. Hadley⁴. ¹Central

Michigan University College of Medicine; ²Ohio

State University College of Medicine; ³University of Michigan Medical School; ⁴UCSF Medical School

868 — B0346 Efficacy of voriconazole on Acanthamoeba Keratitis: Prospective Randomized Double masked trial. Bhupesh Bagga¹, S. Sharma², R. gour¹, J. Joseph Ruben², A. Mohamed¹. ¹Cornea, L.V.Prasad Eye institute, Hyderabad; ²Jhaveri Microbiology centre, L.V.Prasad Eys institute ⊀¹

869 — B0347 Comparison Study on Aspergillus Pathogenicity of Corneal Clinical Isolates And Standard Strain: The Relationship Between Invasiveness And Growth Characteristics. Yingyu Li, P. Zhang, Z. Liu, W. Wang. Ophthalmology, Peking University Third Hospital

870 — B0348 Role of Circumferential Full Thickness Scleral Debridement in Fulminant Infective Ring Scleritis. Samendra Karkhur^{1, 2}, A. Sen¹, P. Shenoy¹, M. Hassan², M. Halim², M. Hasanreisoglu³, R. Afridi², Y. Sepah², D. V. Do², Q. D. Nguyen², V. Gupta⁴. ¹Retina & Uvea Service, Department of Ophthalmology, , Sadguru Netra Chikitsalaya; ²Spencer Center for Vision Research, Byers Eye Institute at Stanford University; ¹Department of Ophthalmology, Gazi University; ¹Department of Ophthalmology, Post Graduate Institute of Medical Education & Research

871 — B0349 Limbal Stem Cell Deficiency
Associated with Herpetic Keratitis: A
Retrospective Study. Jimena T. Carreno-Galeano,
T. Dohlman, J. Yin, R. Dana. Schepens Eye
Research Institute, Massachusetts Eye and Ear
Infirmary, Harvard Medical School

872 — B0350 Undiagnosed Ocular Syphilis Treated with Biologic Immunosuppressive Therapy. Andrew Pittner, P. Merrill, P. Patel. Ophthalmology, Rush University Medical Center

873 — B0351 Ocular Manifestations of Disseminated Mycobacterium Chimaera Infection After Cardiothoracic Surgery. Jingyi Ma, N. Carrell, C. Baker. University of Alberta

874 — B0352 Cryptococcal choroiditis in the absence of cryptococcal meningitis: a novel clinical description. Doran Spencer, A. Yarmohammadi, C. B. Toomey, T. Ofstad, W. R. Freeman. Shiley Eye Institute, Univ. of Calif., San Diego

875 — B0353 Electroretinography and Visual Function among Individuals Infected with Human Immunodeficiency Virus. Davin C. Ashraf¹, L. D. Alves³, A. K. Goldberg², G. N. Holland³.⁴, F. Yu³, S. Nusinowitz³. ¹Department of Ophthalmology, University of California, San Francisco; ²Department of Ophthalmology, University of Texas Health Science Center of Houston; ³Department of Ophthalmology, UCLA Stein Eye Institute; ⁴Ocular Inflammation Disease Center, UCLA Stein Eye Institute; ⁵Department of Ophthalmology, Universidade Federal de Goiás

876 — B0354 Decreased optic nerve head blood flow in acute retinal necrosis. Hiroshi Keino, M. Nakayama, T. Watanabe, Y. Ando, T. Koto, K. Hirota, M. Inoue, A. Okada. Ophthalmology, Kyourin Univ Sch of Med



The Association for Research in Vision and Ophthalmology

1801 Rockville Pike, Suite 400 Rockville, MD 20852-5622 Tel: +1.240.221.2900

ARVO.org